On this weeks episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets ...

Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, ...

After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

On this weeks episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

Collaboration and licensing agreements are an indispensable business strategy for both pharmaceutical companies with commercial capabilities and biotech companies developing novel therapeutics. With ...

As generative artificial intelligence (GenAI) continues to permeate the life sciences industry, several key applications have risen in adoption — and have seen the most impact — within the industry.

Achieving regulatory approval for a new drug is an extraordinary achievement. The bar for success is high. Many companies with breakthrough scientific discoveries and promising clinical data still ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...